The quest for clearer skin is entering a new era, one powered by artificial intelligence. Eau Thermale Avène, a leading dermo-cosmetic brand, is partnering with Toulouse-based health technology firm BotDesign to integrate AI into a clinical study focused on acne treatment. This collaboration, announced this week, marks what the company claims is a first in the dermo-cosmetics industry – the application of artificial intelligence to the rigorous process of clinical research. The initial focus will be on evaluating the effectiveness of Avène Cleanance Comedomed+ in maintaining improvements after patients complete treatment with oral isotretinoin, a powerful medication often used for severe acne.
For individuals grappling with persistent acne, the journey doesn’t end when the prescription runs out. Maintaining the gains achieved through medications like isotretinoin can be a significant challenge. This study, planned to begin in 2026, aims to determine if a targeted skincare regimen, specifically with Avène Cleanance Comedomed+, can help sustain those improvements and potentially reduce the likelihood of relapse. Understanding the long-term maintenance of acne remission is a critical area of research, as isotretinoin, while effective, carries potential side effects and isn’t always a long-term solution. The use of isotretinoin is often carefully managed by dermatologists due to its potency.
AI’s Role in Refining Acne Treatment Research
The integration of AI isn’t about replacing traditional clinical trial methods, but rather enhancing them. BotDesign specializes in applying AI to healthcare, and their technology will likely be used to analyze the vast amounts of data generated during the study – everything from patient-reported outcomes to clinical assessments of skin condition. This could lead to more precise identification of patterns and correlations, potentially revealing which patients benefit most from the maintenance therapy, and why. According to Avène, this represents a broader initiative by parent company Pierre Fabre Laboratories to explore how AI can revolutionize clinical studies in dermatology and skincare.
Dr. Gautier Doat, Medical Director at Eau Thermale Avène, emphasized the company’s unique position to lead this kind of innovation. “We belong to a group that has always been rooted in pharmaceuticals and dermo-cosmetics,” he stated. “Our medical expertise gives us a head start in understanding patients and their pathologies. We are ideally positioned to offer treatment protocols based on the pathology, combining dermo-cosmetics with medication.” He further explained that the long-term usability of dermo-cosmetics, unlike many pharmaceutical treatments, allows for sustained care and potential preventative benefits. The company is actively developing innovations designed to complement and extend the effects of medical treatments, or even delay the need for them.
A “Supportive Care” Strategy for Enhanced Patient Outcomes
This project aligns with Pierre Fabre’s “Supportive Care” strategy, launched in 2025, which centers on combining dermo-cosmetic products with medical treatments to improve patient outcomes. The goal is to move beyond simply treating symptoms and towards a more holistic approach that supports the overall health of the skin and the well-being of the patient. This strategy recognizes that skincare isn’t always a standalone solution, and that integrating it with medical interventions can yield better, more lasting results. The “Supportive Care” strategy is a key pillar of Pierre Fabre’s long-term vision for dermatology.
The potential benefits of using AI in this context are numerous. Traditional clinical trials can be time-consuming and expensive, often relying on subjective assessments. AI-powered analysis could help to standardize evaluations, reduce bias, and accelerate the process of identifying effective treatments. It could also allow researchers to personalize treatment plans based on individual patient characteristics, leading to more targeted and effective care. The use of AI in dermatology is a growing field, with applications ranging from early detection of skin cancer to personalized skincare recommendations.
Looking Ahead: The 2026 Clinical Trial and Beyond
While the study is still in the planning stages, the collaboration between Avène and BotDesign signals a significant shift in how dermo-cosmetic research is conducted. The trial will focus on adults with severe to very severe acne who have recently completed a course of oral isotretinoin. Researchers will be closely monitoring participants to assess whether Cleanance Comedomed+ can help maintain the improvements achieved during medication therapy. The specific parameters of the study, including the number of participants and the duration of the trial, have not yet been released.
The integration of advanced data analysis and AI capabilities into clinical research within the dermo-cosmetics sector is a step towards a more data-driven and personalized approach to skincare. This isn’t just about finding better products; it’s about understanding the complex interplay between skin health, medical treatments, and individual patient needs. As AI technology continues to evolve, we can expect to see even more innovative applications in the field of dermatology, ultimately leading to more effective and tailored treatments for a wide range of skin conditions.
The next key milestone will be the launch of the clinical trial in 2026. Further details regarding participant recruitment and study protocols will be announced closer to that date. For updates on this research and other advancements in dermo-cosmetic science, visit the Eau Thermale Avène website.
Have thoughts on the use of AI in skincare? Share your comments below, and let us know what innovations you’d like to see in the future.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It’s essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
